AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17934877 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessment during ERT
Number of subjects: 47
Study 12525234 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins (LMWHs)
Number of subjects: 31
Study 10611140 — intervention group
Group type: EXPERIMENTAL
Intervention: Eletriptan (25 microM)
Number of subjects: 0
Study 10611140 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin (25 microM)
Number of subjects: 0
Study 10611140 — intervention group
Group type: EXPERIMENTAL
Intervention: Eletriptan (5 microM and lower)
Number of subjects: 0
Study 10611140 — intervention group
Group type: EXPERIMENTAL
Intervention: Eletriptan (maximum blood concentration 0.5 microM after therapeutic dose)
Number of subjects: 0
Study 10611140 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical study (not specified)
Number of subjects: 0
Study 9360003 — intervention group
Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure < or = 90 mmHg
Number of subjects: 18790
Study 9360003 — intervention group
Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure < or = 85 mmHg
Number of subjects: 18790
Study 9360003 — intervention group
Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure < or = 80 mmHg
Number of subjects: 18790
Study 9360003 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly subgroup (< or = 90 mmHg)
Number of subjects: 18790
Study 9360003 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly subgroup (< or = 85 mmHg)
Number of subjects: 18790
Study 9360003 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly subgroup (< or = 80 mmHg)
Number of subjects: 18790
Study 9360003 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (5 mg once daily)
Number of subjects: 18790
Study 9360003 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects
Number of subjects: 18790
Study 1559314 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (4 times daily administration)
Number of subjects: 4
Study 1559314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 2996820 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 8
Study 2996820 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril + Naloxone
Number of subjects: 8
Study 2996820 — intervention group
Group type: COMPARATOR
Intervention: Naloxone
Number of subjects: 8
Study 31655588 — intervention group
Group type: EXPERIMENTAL
Intervention: Village Health and Nutrition Days (VHNDs)
Number of subjects: 452
Study 28668558 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation (exercise therapy) for 6 to 8 weeks
Number of subjects: 0
Study 28668558 — intervention group
Group type: COMPARATOR
Intervention: No referral
Number of subjects: 0
Study 25919246 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 45
Study 25919246 — intervention group
Group type: COMPARATOR
Intervention: IncobotulinumtoxinA
Number of subjects: 45
Study 22892123 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 6505
Study 22892123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6505
Study 20980920 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's Wort (SJW) 300 mg three times a day for 14 days in volunteers
Number of subjects: 130
Study 20980920 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's Wort (SJW) in patients
Number of subjects: 130
Study 20980920 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients
Number of subjects: 130
Study 19526764 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanhuang Qingxue Yin (SQY) plus conventional Western medical therapy
Number of subjects: 120
Study 19526764 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medical therapy only
Number of subjects: 120
Study 17255240 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass oral azithromycin distribution
Number of subjects: 0
Study 17255240 — intervention group
Group type: COMPARATOR
Intervention: Untreated villages
Number of subjects: 0
Study 17255240 — intervention group
Group type: EXPERIMENTAL
Intervention: Children treated with antibiotics
Number of subjects: 0
Study 15475131 — intervention group
Group type: EXPERIMENTAL
Intervention: Biplanar insoles
Number of subjects: 0
Study 15475131 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobra insoles
Number of subjects: 0
Study 15475131 — intervention group
Group type: COMPARATOR
Intervention: No insole condition
Number of subjects: 0
Study 11529282 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort Turbuhaler) 160/4.5 microg, two inhalations b.i.d.
Number of subjects: 362
Study 11529282 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide plus formoterol via separate inhalers
Number of subjects: 362
Study 11529282 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol (Symbicort Turbuhaler) and budesonide plus formoterol via separate inhalers
Number of subjects: 362
Study 9706854 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg the first day followed by 100 mg per day
Number of subjects: 32
Study 9706854 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg per day
Number of subjects: 32
Study 9706854 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline plus ibuprofen scheduled as in groups 1 and 2
Number of subjects: 32
Study 9706854 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule/day (control)
Number of subjects: 32
Study 8572869 — intervention group
Group type: EXPERIMENTAL
Intervention: Active antihypertensive treatment with dihydropyridine felodipine, with a focus on achieving DBP < or = 90 mmHg.
Number of subjects: 10005
Study 8572869 — intervention group
Group type: COMPARATOR
Intervention: Previous treatment before randomization.
Number of subjects: 10005
Study 2143092 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic treatment
Number of subjects: 741
Study 2143092 — intervention group
Group type: COMPARATOR
Intervention: Hospital outpatient management
Number of subjects: 741
Study 354977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethylene vinyl acetate modified IUM
Number of subjects: 300
Study 354977 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydron coated IUM
Number of subjects: 300
Study 354977 — intervention group
Group type: COMPARATOR
Intervention: Standard IUM
Number of subjects: 300
Study 30874378 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 20 mg/d before bedtime for 2 weeks
Number of subjects: 82
Study 30874378 — intervention group
Group type: COMPARATOR
Intervention: Placebo before bedtime for 2 weeks
Number of subjects: 82
Study 28579225 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care CD4 cell counts
Number of subjects: 770
Study 28579225 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care CD4 cell counts
Number of subjects: 770
Study 26066780 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus 12 sessions of individual music therapy (n = 15)
Number of subjects: 30
Study 26066780 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment only (n = 15)
Number of subjects: 30
Study 23173979 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity over 12 months
Number of subjects: 256
Study 23173979 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma self-management instruction
Number of subjects: 256
Study 22308846 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (32 patients)
Number of subjects: 56
Study 22308846 — intervention group
Group type: COMPARATOR
Intervention: Placebo (24 patients)
Number of subjects: 56
Study 19114868 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervicovaginal secretions (CVS) from participants acquiring HIV (cases)
Number of subjects: 0
Study 19114868 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervicovaginal secretions (CVS) from participants with bacterial sexually transmitted infections
Number of subjects: 0
Study 19114868 — intervention group
Group type: COMPARATOR
Intervention: Cervicovaginal secretions (CVS)
Number of subjects: 0
Study 16075184 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 41
Study 16075184 — intervention group
Group type: EXPERIMENTAL
Intervention: All antidepressants
Number of subjects: 41
Study 16075184 — intervention group
Group type: COMPARATOR
Intervention: Tricyclics
Number of subjects: 41
Study 12834314 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended anticoagulant therapy (6 months for temporary risk factors or 1 year for idiopathic pulmonary embolism)
Number of subjects: 326
Study 12834314 — intervention group
Group type: COMPARATOR
Intervention: Discontinue treatment
Number of subjects: 326
Study 12834314 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended anticoagulation (for idiopathic venous thromboembolism)
Number of subjects: 326
Study 12834314 — intervention group
Group type: COMPARATOR
Intervention: Discontinue treatment (for idiopathic venous thromboembolism)
Number of subjects: 326
Study 12834314 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended anticoagulation
Number of subjects: 326
Study 10571341 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible endpoint burns
Number of subjects: 152
Study 10571341 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold (invisible) lesions
Number of subjects: 152
Study 10571341 — intervention group
Group type: COMPARATOR
Intervention: Treated eyes (both visible burns and subthreshold lesions)
Number of subjects: 152
Study 8911976 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (1-8 mg once daily)
Number of subjects: 1044
Study 8911976 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (2.5-20 mg)
Number of subjects: 1044
Study 1725891 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 40 mg, twice daily
Number of subjects: 20
Study 1725891 — intervention group
Group type: COMPARATOR
Intervention: Captopril 50 mg, twice daily
Number of subjects: 20
Study 7041654 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin‐gentamicin
Number of subjects: 49
Study 7041654 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 49
Study 7041654 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 49
Study 4002803 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral muzolimine 120 mg
Number of subjects: 6
Study 4002803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31609422 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HFD) providing 50% excess energy from fat, n = 10
Number of subjects: 20
Study 31609422 — intervention group
Group type: COMPARATOR
Intervention: Eucaloric diet (control), n = 10
Number of subjects: 20
Study 31609422 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HFD and control) during immobilization
Number of subjects: 20
Study 29172782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribulus terrestris
Number of subjects: 40
Study 29172782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 26782031 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 min/week of moderate-intensity aerobic exercise and twice-weekly supervised strength training
Number of subjects: 61
Study 24684838 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg quarterly ranibizumab
Number of subjects: 353
Study 24684838 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg quarterly ranibizumab
Number of subjects: 353
Study 24684838 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg monthly ranibizumab
Number of subjects: 353
Study 24684838 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading phase of ranibizumab therapy
Number of subjects: 353
Study 24684838 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence of intraretinal cysts during follow-up
Number of subjects: 353
Study 24684838 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence of subretinal fluid during follow-up
Number of subjects: 353
Study 24684838 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline pigment epithelial detachments
Number of subjects: 353
Study 22669289 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-875 (25, 50, 100, 200, or 400 mg, orally, once daily for 14 days)
Number of subjects: 59
Study 22669289 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-875
Number of subjects: 59
Study 22669289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 19495871 — intervention group
Group type: EXPERIMENTAL
Intervention: Viabil-covered stent
Number of subjects: 60
Study 19495871 — intervention group
Group type: COMPARATOR
Intervention: Bare Wallstent
Number of subjects: 60
Study 18517094 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-mediated intervention (CIN)
Number of subjects: 507
Study 18517094 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 507
Study 15851648 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure goal of 102 to 107 mm Hg (usual)
Number of subjects: 1094
Study 15851648 — intervention group
Group type: COMPARATOR
Intervention: Mean arterial pressure goal of 92 mm Hg or less (lower)
Number of subjects: 1094
Study 15851648 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment with beta-blocker (metoprolol)
Number of subjects: 1094
Study 15851648 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment with angiotensin-converting enzyme inhibitor (ramipril)
Number of subjects: 1094
Study 15851648 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment with dihydropyridine calcium channel blocker (amlodipine)
Number of subjects: 1094
Study 12881389 — intervention group
Group type: EXPERIMENTAL
Intervention: PELF
Number of subjects: 200
Study 12881389 — intervention group
Group type: COMPARATOR
Intervention: FAMTX
Number of subjects: 200
Study 10087825 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia with restricted dose of fentanyl (20 micrograms.kg‐1)
Number of subjects: 34
Study 10087825 — intervention group
Group type: COMPARATOR
Intervention: Benzodiazepine-fentanyl regimen (control group)
Number of subjects: 34
Study 8550838 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (24 mg/min)
Number of subjects: 20
Study 1859521 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosialoganglioside
Number of subjects: 119
Study 1859521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 6651208 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 102
Study 6651208 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 102
Study 6651208 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 102
Study 6651208 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 102
Study 6651208 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone
Number of subjects: 102
Study 31445039 — intervention group
Group type: EXPERIMENTAL
Intervention: Traction-assisted endoscopic submucosal dissection (TA-ESD)
Number of subjects: 116
Study 31445039 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopic submucosal dissection (ESD)
Number of subjects: 116
Study 31237875 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based walking intervention
Number of subjects: 1297
Study 29438540 — intervention group
Group type: COMPARATOR
Intervention: Caloric restriction (CR)
Number of subjects: 36
Study 29438540 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction + sleep restriction (CR + SR)
Number of subjects: 36
Study 27045002 — intervention group
Group type: EXPERIMENTAL
Intervention: HTC service delivery by Village Health Teams (VHTs) integrated with family planning services.
Number of subjects: 256
Study 27045002 — intervention group
Group type: COMPARATOR
Intervention: Control group providing family planning only.
Number of subjects: 256
Study 24886409 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose OFS+P (30 g/d)
Number of subjects: 96
Study 24886409 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose OFS+P (15 g/d)
Number of subjects: 96
Study 24886409 — intervention group
Group type: COMPARATOR
Intervention: Control (maltodextrin 15 g/d)
Number of subjects: 96
Study 22914998 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg daily for nine months
Number of subjects: 44
Study 22914998 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteer group (control)
Number of subjects: 44
Study 22914998 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 44
Study 20837464 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based tailored advice
Number of subjects: 2099
Study 20837464 — intervention group
Group type: COMPARATOR
Intervention: Control group (static web pages with general information)
Number of subjects: 2099
Study 18598765 — intervention group
Group type: COMPARATOR
Intervention: 0.0% DHEA
Number of subjects: 40
Study 18598765 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% DHEA
Number of subjects: 40
Study 18598765 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% DHEA
Number of subjects: 40
Study 18598765 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8% DHEA
Number of subjects: 40
Study 16051946 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy‐General (FACT‐G)
Number of subjects: 1268
Study 16051946 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Living Index‐Cancer (FLIC)
Number of subjects: 1268
Study 16051946 — intervention group
Group type: COMPARATOR
Intervention: EORTC QLQ‐C30
Number of subjects: 1268
Study 12477680 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg x kg(-1) of 1% propofol and 3 mg x kg(-1) of 2.5% thiopentone (P/T)
Number of subjects: 127
Study 12477680 — intervention group
Group type: COMPARATOR
Intervention: 5 mg x kg(‐1) of 1% propofol and 1 mg x kg(‐1) of lidocaine (P/L)
Number of subjects: 127
Study 10391165 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhomboid flap transposition
Number of subjects: 46
Study 10391165 — intervention group
Group type: COMPARATOR
Intervention: Deep suturing technique
Number of subjects: 46
Study 8728349 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times a day for 6 days
Number of subjects: 18
Study 8728349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1857482 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril 20 mg o.d.
Number of subjects: 12
Study 1857482 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 50 mg o.d.
Number of subjects: 12
Study 1857482 — intervention group
Group type: EXPERIMENTAL
Intervention: chlorthalidone 12.5 mg o.d.
Number of subjects: 12
Study 1857482 — intervention group
Group type: COMPARATOR
Intervention: placebo o.d.
Number of subjects: 12
Study 6220870 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 1.5 percent topical solution
Number of subjects: 20
Study 6220870 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin phosphate 1.0 percent topical solution
Number of subjects: 20
Study 31692212 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Management Review service (MMR)
Number of subjects: 73
Study 30159666 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG anti-HEV antibody testing
Number of subjects: 1799
Study 30159666 — intervention group
Group type: EXPERIMENTAL
Intervention: Age groups analysis for IgG anti-HEV positivity
Number of subjects: 1799
Study 30159666 — intervention group
Group type: EXPERIMENTAL
Intervention: HEV RNA testing
Number of subjects: 1799
Study 27512816 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive stretching with continuous vibration (PS+VIB)
Number of subjects: 14
Study 27512816 — intervention group
Group type: COMPARATOR
Intervention: Passive stretching only (PS+CON)
Number of subjects: 14
Study 27512816 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PS+CON and PS+VIB
Number of subjects: 14
Study 24617764 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinyl isolation bag
Number of subjects: 59
Study 24617764 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene wrap
Number of subjects: 59
Study 23756585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified milk (MG)
Number of subjects: 108
Study 23756585 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 108
Study 19862820 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (25 mg/d on Days 1‐21 of a 28‐day cycle)
Number of subjects: 306
Study 19862820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 17697909 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (5 to 30 mg/kg per day)
Number of subjects: 586
Study 17697909 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine (DFO) (20 to 60 mg/kg per day)
Number of subjects: 586
Study 16133467 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar electrodissection tonsillectomy
Number of subjects: 40
Study 16133467 — intervention group
Group type: COMPARATOR
Intervention: Cold dissection tonsillectomy
Number of subjects: 40
Study 12404142 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (supine position after 5 minutes)
Number of subjects: 60
Study 12404142 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (lateral position for 15 minutes)
Number of subjects: 60
Study 10453871 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained group (participated in initial and maintenance workshops)
Number of subjects: 30
Study 10453871 — intervention group
Group type: COMPARATOR
Intervention: Usual group (no formal training until week 12)
Number of subjects: 30
Study 7614647 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg.kg‐1 before CPB and before declamping of aorta)
Number of subjects: 27
Study 7614647 — intervention group
Group type: COMPARATOR
Intervention: Non-Methylprednisolone treated patients (control)
Number of subjects: 27
Study 2517323 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg/day orally for 3 days, starting 1 day before X-ray examination)
Number of subjects: 35
Study 2517323 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 35
Study 2517323 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 35
Study 1013675 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (3 X 50 mg day)
Number of subjects: 5
Study 1013675 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 5